目的 探討通竅耳聾丸聯(lián)合巴曲酶注射液治療突發(fā)性耳聾的臨床療效。方法 選擇2018年7月—2020年12月在鄭州大學(xué)第一附屬醫(yī)院治療的102例突發(fā)性耳聾患者，根據(jù)用藥的差別分為對照組和治療組，每組各51例。對照組靜脈滴注巴曲酶注射液，初次10 UB，以后每次5 UB加入150 mL生理鹽水。治療組在對照組基礎(chǔ)上口服通竅耳聾丸，6 g/次，2次/d。兩組患者均經(jīng)2周治療。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀改善時(shí)間及紅細(xì)胞壓積（HCT）、全血黏度（WBV）、纖維蛋白原（FIB）和血漿黏度（PV）水平。結(jié)果 經(jīng)治療，對照組和治療組總有效率分別為84.31%、98.04%（P<0.05）。經(jīng)治療，治療組患者癥狀改善時(shí)間明顯早于優(yōu)于對照組（P<0.05）。經(jīng)治療，兩組HCT、WBV、FIB和PV均明顯降低（P<0.05），且治療組患者指標(biāo)下降更明顯（P<0.05）。結(jié)論 通竅耳聾丸聯(lián)合巴曲酶注射液治療突發(fā)性耳聾患者，不僅可改善臨床癥狀，還可改善血液流變學(xué)指標(biāo)，具有一定臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Tongqiao Erlong Pills combined with Batroxobin Injection in the treatment of sudden deafness. Methods Patients (102 cases) with sudden deafness in the First Affiliated Hospital of Zhengzhou University from July 2018 to December 2020 were divided into control and treatment groups according to the difference of medication, and each group had 51 cases. Patients in the control group were po administered with Batroxobin Injection, the first dose was 10 UB, then 5 UB Batroxobin Injection was added into 150 mL normal saline. Patients in the treatment group were po administered with Tongqiao Erlong Pills, 6 g/time, twice daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical evaluation was evaluated, the disappearance time of clinical symptoms, the levels of HCT, WBV, FIB, and PV in two groups before and after treatment were compared. Results After treatment, the effective rates of the control group and the treatment group were 84.31% and 98.04%, respectively (P<0.05). After treatment, the time of symptom improvement in the treatment group was significantly earlier than that in the control group (P<0.05). After treatment, HCT, WBV, FIB, and PV in two groups were significantly decreased (P<0.05), and the indexes of patients in the treatment group were decreased more significantly (P<0.05). Conclusion Tongqiao Erlong Pills combined with batroxobin in treatment of sudden deafness can not only improve clinical symptoms, but also improve hemorheological indexes, which has a certain clinical application value.

R987

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃（聯(lián)合共建）項(xiàng)目（LHGJ20190317）